查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995236

药物释放型支架市场：按类型、药物、应用、最终用户和分销管道划分－2026-2032年全球市场预测

Drug Eluting Stent Market by Type, Drug, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，药物释放型支架市场价值将达到 63.5 亿美元，到 2026 年将成长至 67.5 亿美元，到 2032 年将达到 112.2 亿美元，复合年增长率为 8.46%。

主要市场统计数据
基准年 2025 63.5亿美元
预计年份：2026年 67.5亿美元
预测年份 2032 112.2亿美元
复合年增长率 (%) 8.46%

全面介绍药物释放型支架的临床意义、设备发展历程、监管途径以及影响其应用的策略挑战。

药物释放型支架已成为介入性心臟病学和血管内治疗中至关重要的治疗工具，并已纳入多种动脉粥状硬化性疾病的现代治疗方案。过去20年间，这些装置从第一代设计发展成为结合了抗增殖药物递送、精密支架和聚合物技术的先进平台。这一发展得益于生物相容性、药物递送和临床疗效的不断改进，以及透过随机对照试验和真实世界临床註册研究持续累积的证据。

对药物释放型支架领域中改变患者预后和市场动态的变革性技术、临床和商业性变化进行分析。

药物释放型支架领域正经历技术、临床和市场因素的整合变革，这些因素共同作用，带来革命性的改变。材料科学的进步使得支架支柱设计更加纤细、生物相容性涂层更加优异成为可能，而药物製剂的创新则进一步提升了这些硬体性能，旨在优化局部抗增殖效果，同时最大限度地减少全身暴露。因此，器械的差异化越来越依赖一些细微的性能特征，例如内皮细胞修復情况、在复杂解剖结构中的递送以及与辅助成像和生理评估工具的兼容性。

对 2025 年美国关税措施及其对供应链、筹资策略和药物释放型支架取得的影响进行详细评估。

美国2025年实施的关税措施可能会对整个全球医疗设备供应链产生连锁反应，影响采购、库存管理和筹资策略。最初的影响将最为显着，尤其是在生产投入品和成品跨境运输时，这些环节将受到关税上涨的影响，迫使采购机构重新评估供应商所在地，并在成本、交货前置作业时间和供应商可靠性之间权衡取舍。为此，一些医疗机构可能会扩大供应商范围，优先选择具有本地生产能力的供应商，或透过合约谈判来降低短期价格波动带来的影响。

细分市场洞察揭示了类型、药物、适应症、最终用户和分销方面的细微差异如何影响临床选择、采购优先事项和商业化。

药物释放型支架领域的细分市场差异会影响临床决策和商业策略，因此，全面了解支架类型、药物、应用、最终用户和分销管道对于掌握市场趋势至关重要。就器械类型而言，市场区分聚合物涂层系统和无聚合物平台。在聚合物涂层产品中，进一步区分了旨在随时间推移被吸收的生物可降解聚合物涂层设计和能够长期保持涂层特性的耐用聚合物涂层结构。这些差异会影响癒合的生物机制、延迟不利事件的发生以及向临床医生传达的关于长期血管通畅性的讯息。

决定药物释放型支架在不同医疗保健系统和经济区域临床引入、购买行为和报销方式的区域趋势。

区域趋势对药物释放型支架的采用、报销和整合到治疗方案中具有显着影响，了解这些差异对于跨国策略和区域性商业化计画至关重要。在美洲，公共和私人支付方的报销框架各不相同，采购方在评估新型支架平台时通常优先考虑临床数据和手术经济性。采购週期可能集中在医院网路内，也可能分散在各个医疗机构，这种多样性会影响製造商如何展示产品价值以及如何谈判供应合约。

在不断变化的临床、监管和支付环境背景下，开发和商业化药物释放型支架的公司的竞争格局和策略重点

药物释放型支架领域的企业竞争格局取决于产品创新、实证医学证据的累积以及展现永续临床和经济价值的能力。成熟的製造商通常凭藉广泛的产品系列、全球监管核准和丰富的上市后数据来保持领先地位，而高度专业化的创新者则致力于透过差异化的设计特征和特定适应症来引领临床应用。那些能够将强大的临床项目与有针对性的真实世界数据（REW）收集相结合的企业，往往对采购决策产生更大的影响，因为它们可以同时解决疗效和长期安全性问题。

为领导者提供可操作的建议，以加速药物释放型支架领域的创新、优化采购并改善临床和商业性成果。

产业领导者可以采取实际措施，加速创新、确保供应连续性、强化商业性地位，同时改善病患疗效。首先，优先制定清晰的证据蓝图，结合随机临床试验和可操作的註册研究，既能满足监管要求，又能解决临床医生和支付方的实际顾虑。其次，投资区域製造能力并实现供应链多元化，包括关键原材料的检验二级供应商，可以降低贸易中断带来的风险，并有助于与大规模医疗系统进行更可预测的采购谈判。

本文总结了药物释放型支架研究中使用的调查方法，包括临床文献的整合、与专家和相关人员的对话、资料检验和分析技术。

本报告的研究结果是基于多方面的研究途径，该方法整合了临床文献、专家和相关人员的见解以及检验的资料来源。分析过程首先对同行评审的临床研究、指南文件和监管申报文件进行系统性回顾，以确定支架技术的临床表现标准。除此二手资料分析外，还与介入性心臟病专家、血管专家、采购经理和分销合作伙伴进行了结构化访谈和咨询，以了解他们对医疗设备选择、手术流程和供应链限制的实际观点。

摘要重点阐述了策略重点、创新需求以及为改善患者疗效和产业韧性而进行的合作努力。

总而言之，由于材料科学的进步、临床实践的演进以及商业性预期的变化，药物释放型支架领域正处于转折点。持续的差异化取决于器械平台能否在适应现代介入医学手术实际情况的同时，展现出具有临床意义的改进。同时，贸易政策的变化以及对弹性供应链的需求等外部压力正在影响采购行为和产品供应，这既给製造商和医疗保健系统带来了挑战，也带来了战略机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：药物释放型支架市场：依类型划分

  • 聚合物涂层
    • 可生物降解聚合物涂层
    • 耐用聚合物涂层
  • 不含聚合物

第九章：按药物类型分類的药物释放型支架市场

  • Biolims溶解型
  • Everolimus洗脱型
  • 紫杉醇洗脱型
  • Sirolimus洗脱型

第十章：药物释放型支架市场：依应用领域划分

  • 冠状动脉疾病
  • 週边血管疾病

第十一章：药物释放型支架市场：依最终用户划分

  • 门诊手术中心
  • 医院

第十二章：药物释放型支架市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：药物释放型支架市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：药物释放型支架市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：药物释放型支架市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国药物释放型支架市场

第十七章：中国药物释放型支架市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Biosensors International Group, Ltd.
  • BIOTRONIK AG
  • Boston Scientific Corporation
  • Elixir Medical Corp
  • Johnson & Johnson
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • Meril Life Sciences Private Limited
  • MicroPort Scientific Corporation
  • Terumo Corporation
Product Code: MRR-807A20B5CCC6

The Drug Eluting Stent Market was valued at USD 6.35 billion in 2025 and is projected to grow to USD 6.75 billion in 2026, with a CAGR of 8.46%, reaching USD 11.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.35 billion
Estimated Year [2026] USD 6.75 billion
Forecast Year [2032] USD 11.22 billion
CAGR (%) 8.46%

Comprehensive introduction outlining clinical relevance, device evolution, regulatory pathways, and strategic imperatives shaping adoption of drug eluting stents

Drug eluting stents have become a pivotal therapeutic intervention in interventional cardiology and vascular medicine, embedding themselves within modern treatment pathways for a range of atherosclerotic conditions. Over the past two decades, these devices have evolved from first-generation designs into sophisticated platforms that balance antiproliferative drug delivery with refined scaffold and polymer technology. This evolution has been driven by iterative improvements in biocompatibility, deliverability, and clinical outcomes, and by a continuous cycle of evidence generation across randomized trials and real-world registries.

Clinicians and procurement leaders now must navigate a landscape in which device choice influences procedural success, long-term vessel patency, and downstream resource utilization. As such, understanding the interplay of device design, drug kinetics, polymer behavior, and clinical indication is central to optimizing patient care and institutional performance. Simultaneously, regulatory scrutiny and payer requirements have shifted priorities toward demonstrable safety and long-term effectiveness, prompting manufacturers to emphasize post-market data and differentiated clinical claims. In this context, the present summary frames the strategic, clinical, and commercial considerations that underpin decision making for stakeholders across hospitals, ambulatory centers, and distribution channels.

Analysis of transformative technological, clinical, and commercial shifts redefining patient outcomes and market dynamics within the drug eluting stent landscape

The drug eluting stent landscape is being reshaped by converging technological, clinical, and market forces that together constitute transformative change. Advances in materials science have enabled thinner strut designs and more biocompatible coatings, and these hardware refinements are complemented by innovations in drug formulation that aim to optimize local antiproliferative effects while minimizing systemic exposure. As a result, device differentiation increasingly rests on nuanced performance characteristics such as endothelial healing profiles, deliverability in complex anatomies, and compatibility with adjunctive imaging and physiologic assessment tools.

Concurrently, clinical practice is evolving: operators are integrating intravascular imaging and physiologic guidance into routine workflows, which alters device selection criteria and procedural approaches. This trend toward precision deployment is creating opportunities for stent platforms that demonstrate predictable and reproducible behavior under image-guided techniques. From a commercial perspective, healthcare systems are emphasizing total cost of care and long-term outcomes, which elevates the importance of robust post-market evidence and value-based contracting. Additionally, the competitive dynamic is intensifying as specialized innovators introduce niche designs while established manufacturers pursue portfolio breadth and lifecycle management. Regulatory expectations have likewise become more rigorous, with stronger emphasis on longer-term safety data and real-world performance, prompting manufacturers to invest in longitudinal registries and adaptive study designs. Taken together, these shifts are redefining how clinical value is demonstrated, how products are procured, and how companies prioritize R&D and market access activities.

In-depth assessment of United States tariff actions in 2025 and their effects on supply chains, procurement strategies, and access to drug eluting stents

The imposition of United States tariff measures in 2025 has the potential to reverberate across global supply chains for medical devices, creating tangible implications for procurement, inventory management, and sourcing strategies. Early effects are most pronounced where manufacturing inputs or finished devices cross borders subject to increased duties, prompting purchasing organizations to reassess supplier footprints and to evaluate the tradeoffs between cost, lead time, and supplier reliability. In response, some health systems may broaden their supplier base, prioritize vendors with local manufacturing capabilities, or negotiate contractual protections to mitigate short-term price volatility.

At the operational level, device manufacturers and distributors are likely to revisit logistics strategies, increasing the emphasis on alternative routing, regional warehousing, and multi-sourcing to preserve continuity of supply. These adjustments can lengthen planning cycles and raise working capital requirements, particularly for high-value implantable devices. Moreover, procurement teams may adjust tender evaluation frameworks to incorporate duty-related cost differentials and supply chain resilience metrics, thereby altering competitive positioning for suppliers whose cost base is sensitive to tariff exposure.

Clinically, stakeholders will need to ensure that any shifts in sourcing do not compromise device quality or clinical outcomes. This necessitates rigorous supplier qualification, accelerated validation of alternative manufacturing sites, and careful management of device transition protocols at the hospital and ambulatory center level. From an innovation standpoint, tariffs can increase incentives for local production and technology transfer, potentially accelerating investments in domestic manufacturing capacity and in-region regulatory submissions. Ultimately, while tariffs may create near-term disruption and cost pressure, they also catalyze strategic shifts that influence how manufacturers and health systems think about resilience, supplier relationships, and geographic diversification of manufacturing.

Segmentation insights revealing how type, drug, application, end user, and distribution nuances drive clinical choice, procurement priorities, and commercialization

Segment-level differentiation in the drug eluting stent space drives both clinical decision making and commercial strategy, and an integrated view of type, drug, application, end user, and distribution channel is essential to appreciate adoption dynamics. Regarding device type, the market distinguishes between polymer coated systems and polymer free platforms; within polymer coated offerings, there is a further split between biodegradable polymer coated designs that aim to resorb over time and durable polymer coated constructs that retain their coating profile long term. These distinctions influence healing biology, late adverse event profiles, and messaging for clinicians focused on long-term vessel patency.

Drug selection represents another axis of differentiation, with devices eluting agents such as biolimus, everolimus, paclitaxel, and sirolimus. Each drug differs in pharmacologic potency, tissue retention characteristics, and historical evidence base, which affects device positioning for specific lesion types and patient risk cohorts. Application context matters as well: the clinical needs and performance expectations for coronary artery disease differ from those for peripheral vascular disease, and device attributes are weighed differently when operators manage challenging peripheral anatomies or seek durable improvement in limb perfusion.

End users also frame purchasing and utilization patterns. Hospitals typically drive higher procedural volumes and manage complex cases requiring a broad set of device options and rapid supply availability, whereas ambulatory surgical centers focus on efficiency, predictable outcomes, and devices that facilitate short-stay workflows. Finally, distribution channels shape access and procurement pathways: hospital pharmacies, online pharmacy platforms, and retail pharmacies each present distinct routing, inventory, and reimbursement considerations that affect how devices reach point-of-care. Taken together, these segmentation dimensions inform product development priorities, evidence generation plans, and commercialization strategies, and they underscore the need for tailored value propositions that resonate with clinicians, supply chain managers, and payers across diverse care settings.

Regional dynamics that determine clinical adoption, purchasing behavior, and reimbursement approaches for drug eluting stents across diverse healthcare systems and economies

Regional dynamics materially influence how drug eluting stents are adopted, reimbursed, and integrated into care pathways, and understanding these differences is critical for multinational strategy and for localized commercialization plans. In the Americas, reimbursement frameworks vary across public and private payers, and purchasers often emphasize comparative clinical data and procedural economics when evaluating new stent platforms. Procurement cycles can be centralized within hospital networks or decentralized across individual institutions, and this variability shapes how manufacturers present value and negotiate supply agreements.

Across Europe, Middle East & Africa the landscape is heterogeneous, with regulatory processes, reimbursement timelines, and clinical practice patterns differing significantly between advanced European markets and emerging economies. In many jurisdictions within this region, health technology assessment outcomes and national procurement programs play an outsized role in determining market access, which requires manufacturers to align clinical evidence packages with payer expectations and to consider regional partnerships to expedite market entry.

In Asia-Pacific, growth in interventional procedures is accompanied by diverse regulatory pathways and varying levels of local manufacturing capability. Some markets prioritize cost-effective devices and demonstrate rapid adoption of technologies that deliver demonstrable improvements in throughput and outcomes, whereas others emphasize domestic industry development and localization. Across all regions, the interplay of clinical training, availability of intravascular imaging, and the structure of hospital reimbursement shapes device selection and the pace at which new platforms gain traction. Therefore, a regionally nuanced approach to evidence generation, pricing, and stakeholder engagement is essential to maximize clinical uptake and to address local system constraints.

Competitive profiles and strategic priorities for companies developing and commercializing drug eluting stents amid clinical, regulatory, and payer shifts

Competitive dynamics among companies engaged with drug eluting stents are defined by product innovation, evidence generation, and the ability to demonstrate sustainable clinical and economic value. Established manufacturers typically leverage broad portfolios, global regulatory clearances, and extensive post-market datasets to maintain leadership, while specialized innovators focus on differentiated design features or niche indications to create pathways for clinical adoption. Firms that balance robust clinical programs with targeted real-world evidence collection tend to influence purchasing decisions more effectively because they can address both efficacy and longer-term safety concerns.

Partnerships and strategic alliances are increasingly important as companies seek to combine complementary capabilities, such as device engineering, drug formulation expertise, and regional market access. Supply chain resilience has become a core strategic priority, prompting manufacturers to diversify production footprints, validate multiple suppliers for critical components, and invest in quality systems that support rapid scaling. Commercially, companies that offer comprehensive training, implementation support, and data-driven value propositions find greater receptivity among hospital systems focused on procedural consistency and outcome optimization. In sum, market leaders and challengers alike must align R&D investments, evidence strategies, and supply chain planning with the shifting expectations of clinicians, health systems, and payers to sustain competitive advantage.

Practical recommendations for leaders to accelerate innovation, optimize procurement, and improve clinical and commercial outcomes in the drug eluting stent space

Industry leaders can take concrete actions to accelerate innovation, safeguard supply continuity, and strengthen commercial positioning while improving patient outcomes. First, prioritizing a clear evidence roadmap that couples randomized clinical studies with pragmatic registries will address both regulatory requirements and the practical concerns of clinicians and payers. Second, investing in supply chain diversification, including regional manufacturing capabilities and validated secondary suppliers for critical inputs, will reduce vulnerability to trade disruptions and support more predictable procurement conversations with large health systems.

Third, aligning product design with the realities of image-guided intervention and emerging care pathways will enhance clinical differentiation; platforms that demonstrably facilitate intravascular imaging, predictable deployment, and consistent healing profiles will be more attractive in settings that demand precision. Fourth, manufacturers should expand commercial models to include value-based contracting pilots and outcome-linked agreements where feasible, enabling closer alignment with health system priorities. Finally, advancing clinician education and deployment support, including procedural training and data-sharing initiatives, will improve uptake and optimize real-world performance. By executing these measures in an integrated manner, industry leaders can balance immediate operational challenges with longer term innovation goals.

Methodology summarizing clinical literature synthesis, expert stakeholder engagement, data validation, and analytical techniques used in drug eluting stent studies

This report's findings are rooted in a multi-method research approach that synthesizes clinical literature, expert stakeholder insights, and validated data sources. The analytical process began with systematic reviews of peer-reviewed clinical studies, guideline documents, and regulatory submissions to establish the clinical performance benchmarks for stent technologies. These secondary-source analyses were complemented by structured interviews and consultations with interventional cardiologists, vascular specialists, procurement leaders, and distribution partners to capture frontline perspectives on device selection, procedural workflow, and supply chain constraints.

Primary data collection included targeted qualitative interviews and the review of anonymized procedural registries to validate patterns observed in the literature. Data triangulation and validation were performed through cross-referencing clinical outcomes with stakeholder feedback and operational considerations, and methodological transparency was maintained by documenting inclusion criteria, interview protocols, and data-cleaning processes. Wherever applicable, results were contextualized against regulatory frameworks and reimbursement practices to ensure that the insights provided reflect both clinical realities and commercial imperatives.

Concluding synthesis stressing strategic priorities, innovation imperatives, and coordinated actions to improve patient outcomes and sector resilience

In synthesis, the drug eluting stent domain is at an inflection point driven by material science advances, evolving clinical practice, and shifting commercial expectations. Continued differentiation will depend on the ability of device platforms to demonstrate clinically meaningful improvements while fitting into the procedural realities of modern interventional practice. At the same time, external pressures such as trade policy changes and the demand for resilient supply chains will influence procurement behavior and product availability, creating both challenges and strategic opportunities for manufacturers and health systems.

To navigate this environment, stakeholders must adopt a coordinated approach that marries robust evidence generation with operational resilience and thoughtful commercialization. Clinical leaders should continue to embrace image-guided and physiology-driven practices, procurement teams must incorporate supply chain risk into purchasing frameworks, and manufacturers need to pursue focused innovation supported by compelling real-world data. This holistic orientation will help ensure that advances in device technology translate into sustained improvements in patient care and durable value for healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Eluting Stent Market, by Type

  • 8.1. Polymer Coated
    • 8.1.1. Biodegradable Polymer Coated
    • 8.1.2. Durable Polymer Coated
  • 8.2. Polymer Free

9. Drug Eluting Stent Market, by Drug

  • 9.1. Biolimus Eluting
  • 9.2. Everolimus Eluting
  • 9.3. Paclitaxel Eluting
  • 9.4. Sirolimus Eluting

10. Drug Eluting Stent Market, by Application

  • 10.1. Coronary Artery Disease
  • 10.2. Peripheral Vascular Disease

11. Drug Eluting Stent Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Drug Eluting Stent Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Drug Eluting Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Eluting Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Eluting Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Eluting Stent Market

17. China Drug Eluting Stent Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Biosensors International Group, Ltd.
  • 18.7. BIOTRONIK AG
  • 18.8. Boston Scientific Corporation
  • 18.9. Elixir Medical Corp
  • 18.10. Johnson & Johnson
  • 18.11. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.12. Medtronic plc
  • 18.13. Meril Life Sciences Private Limited
  • 18.14. MicroPort Scientific Corporation
  • 18.15. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 142. G7 DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 143. G7 DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 149. NATO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 150. NATO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)